Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Y Zhong

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Human Vaccines & Immunotherapeutics|November 10, 2023
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinomaAlbert Jang, Jake N Lichterman, Jeffrey Y Zhong, et al.
Cancers|February 27, 2026
Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder CancerAbby L Grier, Jeffrey Y Zhong, Spyridon Basourakos, et al.
Kidney Cancer (Clifton, Va.)|July 1, 2025
Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized phase 3 trialsAlbert Jang, Jeffrey Y Zhong, Hamsa L S Kumar, et al.
Clinical Genitourinary Cancer|January 13, 2026
Non-Immunotherapy Arm Allocations in Phase 3 Genitourinary Cancer Trials with ImmunotherapyAbby L Grier, Albert Jang, Jeffrey Y Zhong, et al.
The Oncologist|December 30, 2025
EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancerAlbert Jang, Peggy Fowler, Kathryn Helminiak, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Human Vaccines & Immunotherapeutics|November 10, 2023
Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinomaAlbert Jang, Jake N Lichterman, Jeffrey Y Zhong, et al.
Cancers|February 27, 2026
Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder CancerAbby L Grier, Jeffrey Y Zhong, Spyridon Basourakos, et al.
Kidney Cancer (Clifton, Va.)|July 1, 2025
Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized phase 3 trialsAlbert Jang, Jeffrey Y Zhong, Hamsa L S Kumar, et al.
Clinical Genitourinary Cancer|January 13, 2026
Non-Immunotherapy Arm Allocations in Phase 3 Genitourinary Cancer Trials with ImmunotherapyAbby L Grier, Albert Jang, Jeffrey Y Zhong, et al.
The Oncologist|December 30, 2025
EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancerAlbert Jang, Peggy Fowler, Kathryn Helminiak, et al.
Pageof 1